ArticleBMJ open gastroenterology2022
Fatty Liver Index is a valid predictor of non-alcoholic fatty liver disease (NAFLD) in pregnancy.
Article in BMJ open gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Association between triglyceride glucose-body mass index and metabolic dysfunction-associated steatotic liver disease in South Korean pregnant women.Scientific reports · 2026Article
- Surveying the features of screening strategies for non-alcoholic fatty liver disease: A scoping review.Journal of education and health promotion · 2026Review
- Fatty liver index in early pregnancy predicts the risk of gestational diabetes mellitus.Frontiers in endocrinology · 2026Article
- Association between the atherogenic index of plasma and non-alcoholic fatty liver disease in Korean pregnant women: secondary analysis of a prospective cohort study.Frontiers in nutrition · 2025Article
- Controlled attenuation parameter (CAP): the clinical value based on MRI-PDFF in children with obesity.Journal of pediatric endocrinology & metabolism : JPEM · 2024Article
- Association between composite dietary antioxidant index and fatty liver index among US adults.Frontiers in nutrition · 2024Article
- Pregnancy outcome in patients with non-alcoholic fatty liver disease: a prospective cohort study.Gastroenterology and hepatology from bed to bench · 2024Article
- The association between fatty liver index and onset of diabetes: secondary analysis of a population-based cohort study.BMC public health · 2023Article
- Rethinking gestational diabetes: hyperglycemia or a cluster of cardiometabolic abnormalities manifested during pregnancy?Archives of endocrinology and metabolism · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the evidence for adverse pregnancy outcomes, non-alcoholic fatty liver disease (NAFLD) is not routinely addressed in early pregnancy. The Fatty Liver Index (FLI) has been proposed as a screening tool for NAFLD in the general population. We aim to develop mathematical models for predicting NAFLD in pregnancy and validate the FLI for first-trimester pregnant women.
methodsBiochemical and biophysical parameters were analysed in pregnant women with period of gestation <12 weeks was done among Rajarata Pregnancy Cohort, Sri Lanka. Fatty liver was graded as (FLG) 0, I or II by ultrasound scan. Binary logistic regression models were employed to identify the factors predicting FLG-II. Six FLIs were developed to predict FLG-II. Validity of the FLIs was compared using the receiver operating characteristic curves.
resultsThe study sample consisted of 632 pregnant women with a mean age of 28.8 years (SD: 5.8 years). Age (OR: 1.6, 95% CI 1.1 to 2.3), body mass index (OR: 1.7, 95% CI 1.1 to 2.5) and gamma-glutamyl transferase levels (OR: 2.1, 95% CI 1.5 to 3.0) were the independent predictors of FLG-II. While the model with liver enzymes provided the best prediction of NAFLD (both FLG I and II) (area under the curve [(AUC]): -0.734), the highest AUC (0.84) for predicting FLG-II was observed with the full model (model with all parameters). The proposed budget model (AUC >0.81) is the best model for screening fatty liver in community health setup.
conclusionFLIs could be used as screening tools for NAFLD based on resource availability in different settings. External validation of the FLI and further investigation of the proposed FLI as a predictor of adverse pregnancy outcomes are recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.